These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
359 related articles for article (PubMed ID: 21674991)
1. A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook. Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ Sci Signal; 2011; 4(170):er2. PubMed ID: 21674991 [TBL] [Abstract][Full Text] [Related]
2. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ Sci Signal; 2011 Mar; 4(166):ra17. PubMed ID: 21447798 [TBL] [Abstract][Full Text] [Related]
3. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Balmanno K; Chell SD; Gillings AS; Hayat S; Cook SJ Int J Cancer; 2009 Nov; 125(10):2332-41. PubMed ID: 19637312 [TBL] [Abstract][Full Text] [Related]
4. Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling. Little AS; Balmanno K; Sale MJ; Smith PD; Cook SJ Biochem Soc Trans; 2012 Feb; 40(1):73-8. PubMed ID: 22260668 [TBL] [Abstract][Full Text] [Related]
5. Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation. Grasso S; Tristante E; Saceda M; Carbonell P; Mayor-López L; Carballo-Santana M; Carrasco-García E; Rocamora-Reverte L; García-Morales P; Carballo F; Ferragut JA; Martínez-Lacaci I Neoplasia; 2014 Oct; 16(10):845-60. PubMed ID: 25379021 [TBL] [Abstract][Full Text] [Related]
6. Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. Tentler JJ; Nallapareddy S; Tan AC; Spreafico A; Pitts TM; Morelli MP; Selby HM; Kachaeva MI; Flanigan SA; Kulikowski GN; Leong S; Arcaroli JJ; Messersmith WA; Eckhardt SG Mol Cancer Ther; 2010 Dec; 9(12):3351-62. PubMed ID: 20923857 [TBL] [Abstract][Full Text] [Related]
7. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644 [TBL] [Abstract][Full Text] [Related]
8. Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation. Lochhead PA; Clark J; Wang LZ; Gilmour L; Squires M; Gilley R; Foxton C; Newell DR; Wedge SR; Cook SJ Cell Cycle; 2016; 15(4):506-18. PubMed ID: 26959608 [TBL] [Abstract][Full Text] [Related]
9. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib. Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325 [TBL] [Abstract][Full Text] [Related]
10. Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9. E J; Xing J; Gong H; He J; Zhang W Tumour Biol; 2015 Feb; 36(2):1091-7. PubMed ID: 25326806 [TBL] [Abstract][Full Text] [Related]
11. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Yeh JJ; Routh ED; Rubinas T; Peacock J; Martin TD; Shen XJ; Sandler RS; Kim HJ; Keku TO; Der CJ Mol Cancer Ther; 2009 Apr; 8(4):834-43. PubMed ID: 19372556 [TBL] [Abstract][Full Text] [Related]
12. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Corcoran RB; Dias-Santagata D; Bergethon K; Iafrate AJ; Settleman J; Engelman JA Sci Signal; 2010 Nov; 3(149):ra84. PubMed ID: 21098728 [TBL] [Abstract][Full Text] [Related]
13. The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance. Sale MJ; Cook SJ Biochem J; 2013 Mar; 450(2):285-94. PubMed ID: 23234544 [TBL] [Abstract][Full Text] [Related]
15. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers. Temraz S; Mukherji D; Shamseddine A Int J Mol Sci; 2015 Sep; 16(9):22976-88. PubMed ID: 26404261 [TBL] [Abstract][Full Text] [Related]
16. Reporter cell lines to screen for inhibitors or regulators of the KRAS-RAF-MEK1/2-ERK1/2 pathway. Weatherdon L; Stuart K; Cassidy M; de la Gándara AM; Okkenhaug H; Muellener M; Mckenzie G; Cook SJ; Gilley R Biochem J; 2024 Mar; 481(6):405-422. PubMed ID: 38381045 [TBL] [Abstract][Full Text] [Related]
17. The Endosomal Protein CEMIP Links WNT Signaling to MEK1-ERK1/2 Activation in Selumetinib-Resistant Intestinal Organoids. Duong HQ; Nemazanyy I; Rambow F; Tang SC; Delaunay S; Tharun L; Florin A; Büttner R; Vandaele D; Close P; Marine JC; Shostak K; Chariot A Cancer Res; 2018 Aug; 78(16):4533-4548. PubMed ID: 29915160 [TBL] [Abstract][Full Text] [Related]
18. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618 [TBL] [Abstract][Full Text] [Related]
19. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines. Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268 [TBL] [Abstract][Full Text] [Related]
20. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Friday BB; Yu C; Dy GK; Smith PD; Wang L; Thibodeau SN; Adjei AA Cancer Res; 2008 Aug; 68(15):6145-53. PubMed ID: 18676837 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]